Global Preclinical Assets Market Report 2024

Preclinical Assets Global Market Report 2024 – By Service (Bioanalysis And DMPK (Drug Metabolism and Pharmacokinetic) studies, Toxicology Testing, Compound Management, Safety Pharmacology, Other Services), By Model Type (Patient Derived Organoid (PDO) Model, Patient Derived Xenograft Model), By End User (Biopharmaceutical Companies, Government Institutes, Other End-Users) – Market Size, Trends, And Global Forecast 2024-2033

Preclinical Assets Global Market Report 2024

Starting Price : $5000.00 | Pages : | Published : January 2024 | Delivery Time: 2-3 business days | Format : pdf

Purchase Options
Request Sample
Request For Discount
FAQs
Customise Your Report
Request For Proposal
Request For Regional Data

Need assistance or more information before the purchase?

Enquire Before Buying
Preclinical Assets Global Market Report 2024

Proud Members Of

checkslacipN checkaoirsN checkscipN
Description Table Of Contents Tables & Figures Market Insights Related Reports

Preclinical Assets Market Definition And Segments

A preclinical asset refers to all clinical trial supplies or equipment for preclinical development that encompasses the activities that link drug discovery in the laboratory to the initiation of human clinical trials. This phase precedes human clinical trials and entails essential feasibility assessments, iterative evaluations, and safety data gathering, typically performed on laboratory animals.

The main types of preclinical asset services are bioanalysis and DMPK (Drug Metabolism and Pharmacokinetic) studies, toxicology testing, compound management, safety pharmacology, and others. Bioanalysis and DMPK (Drug Metabolism and Pharmacokinetic) studies constitute crucial components of the drug development process, focusing on assessing the pharmacokinetic and drug metabolism characteristics of potential new drugs. The types of models included are patient-derived organoid (PDO) model and the patient-derived xenograft model, which are used by several end users, including biopharmaceutical companies, government institutes, and others.

The preclinical assets market covered in this report is segmented –

1) By Service: Bioanalysis And DMPK (Drug Metabolism and Pharmacokinetic) studies, Toxicology Testing, Compound Management, Safety Pharmacology, Other Services

2) By Model Type: Patient Derived Organoid (PDO) Model, Patient Derived Xenograft Model

3) By End User: Biopharmaceutical Companies, Government Institutes, Other End-Users

The preclinical assets market size has grown strongly in recent years. It will grow from $5.32 billion in 2023 to $5.83 billion in 2024 at a compound annual growth rate (CAGR) of 9.7%. The growth in the historic period can be attributed to drug development needs, advancements in biotechnology, regulatory requirements, research funding growth, collaborative research efforts.

The preclinical assets market size is expected to see strong growth in the next few years. It will grow to $8.34 billion in 2028 at a compound annual growth rate (CAGR) of 9.3%. The growth in the forecast period can be attributed to precision medicine and personalized therapies, ai and machine learning integration, biobanking expansion, focus on rare diseases, government initiatives and funding. Major trends in the forecast period include emergence of advanced imaging techniques, 3d organoid models, multi-omics integration, enhanced predictive models, automation and high throughput screening.

Increasing Drug Discovery

Increasing drug discovery is expected to propel the growth of the preclinical asset market going forward. Drug discovery refers to the process of finding chemical substances that could be used as medicinal agents. It is the process by which new candidate medications are discovered. Within this process, preclinical assets play a vital role by supplying essential data and evidence to aid in the selection of molecules for clinical development as candidates. For instance, in January 2022, according to the Regulatory Affairs Professionals Society, a US-based regulatory organization of healthcare and related products, overall, 37 drugs (74%) in 2021 were approved by the US Food and Drug Administration (FDA) through at least one expedited pathway, an increase from 68% of novel drugs in 2020. Furthermore, in June 2023, according to the Pharma R&D Annual Review 2022 published by Pharma Intelligence, a UK-based provider of tools and solutions for pharmaceutical management, the number of drugs in the R&D pipeline grew from 17,737 in 2020 to 20,109 in 2022. Therefore, increasing drug discovery is driving the growth of the preclinical assets market.

Preclinical Asset Market Growth Through The Mitigation Of Clinical Trial Expenses

The growing need to curb clinical trial costs is expected to propel the growth of the preclinical asset market going forward. Clinical trial costs refer to the expenses associated with planning, conducting, and managing a clinical trial to test the safety, efficacy, and potential benefits of a new medical intervention, such as a drug, medical device, or treatment protocol. These trials provide essential insights into the safety, efficacy, and potential side effects of preclinical assets, helping to validate their therapeutic potential in human subjects. For instance, in February 2023, according to Genetic Engineering and Biotechnology News, a US-based platform that provides the latest information on genetic engineering and biotechnology, developing a new drug among the top 20 global biopharma companies rose by 15%, from $298 million in 2022, to approximately $2.3 billion in 2023, and this includes the costs incurred from developing a drug through clinical trials. Therefore, growing need to curb clinical trial is driving the growth of the preclinical assets market.

Major companies operating in the preclinical assets market report are Laboratory Corporation of America, IQVIA Inc., ICON PLC, Eurofins Scientific SE, PPD Inc., SGS SA, WuXi AppTec Co. Ltd., Intertrek Group PLC, Charles River Laboratories International Inc., Medpace Inc., Pharmaron Beijing Co. Ltd., Evotec SE, GenScript Biotech Corporation, Inotiv Inc., SRI International Inc., Shanghai Medicilon Inc., Biocytogen Pharmaceuticals Beijing Co. Ltd., AmplifyBio LLC, BioReliance Corporation, Pharmalegacy Laboratories Co. Ltd., Precigen Inc., ReproCELL Incorporated, InSphero AG, Crown Bioscience Inc., Comparative Biosciences Inc., TCG Lifesciences Pvt. Ltd., InVivo Biosystems, Pharmatest Services Ltd., Domainex Limited, Viroclinics Xplore

Charles River Laboratories And Valo Health Optimized Preclinical Assets

Product innovations are a key trend gaining popularity in the preclinical assets market. Major companies operating in the preclinical assets market are focused on innovating new products and solutions to strengthen their market position and gain a competitive advantage. For instance, in April 2022, Charles River Laboratories International, a US-based pharmaceutical company specializing in a variety of preclinical and clinical laboratories, and Valo Health Inc., a US-based technology company built to transform drug discovery, launched Logica, an artificial intelligence (AI)-powered drug solution that directly translates clients' biological insights into optimized preclinical assets. Logica leverages Charles River's superior preclinical knowledge and Valo's AI-powered Opal Computational Platform to give clients transformed drug discovery through a single integrated offering that effortlessly translates targets to candidate nomination. By partnering with Valo, Charles River combines its laboratory expertise with molecular design technology, revolutionizing the industry to give its clients highly qualified leads and candidates while connecting client costs to value creation.

AbbVie And Calibr Forge Expanded Strategic Partnership To Advance Preclinical Assets

Major companies operating in the preclinical assets market are focused on forming strategic alliances to strengthen their position in the market. For instance, in July 2023, AbbVie, US- based pharmaceutical company and Calibr, India based leaders in research, drug development, announced an expanded strategic collaboration to continue to advance several innovative preclinical and early-stage clinical assets. The partnership is an extension of the collaboration from AbbVie and Scripps Research. Further, Calibr will present AbbVie with a certain number of new discovery targets and preclinical assets of mutual interest for option considerations.

Pfizer Expands Portfolio With Biohaven's Preclinical Assets In CGPR Receptor Antagonists

In October 2022, Pfizer Inc., a US-based pharmaceutical and biotechnology corporation, acquired Biohaven Pharmaceutical Holding Company Ltd. for $11.6 billion. With the acquisition, Pfizer gained access to a potential portfolio of calcitonin gene-related peptide (CGRP) receptor antagonists, which includes Rimegepant, Zavegepant, and a portfolio of preclinical CGRP assets. Biohaven Pharmaceutical Holding Company Ltd. is a US-based clinical-stage biopharmaceutical company with several preclinical assets in its early discovery program.

North America was the largest region in the preclinical assets market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the preclinical assets market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the preclinical assets market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

The preclinical assets market consists of revenues earned by entities by providing preclinical assets services such as process research and development, asymmetric synthesis, safety pharmacology, and custom synthesis. The market value includes the value of related goods sold by the service provider or included within the service offering. The preclinical assets market consists of sales of chemical compounds, biological samples, and sample storage systems. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

The preclinical assets market research report is one of a series of new reports from The Business Research Company that provides preclinical assets market statistics, including preclinical assets industry global market size, regional shares, competitors with a preclinical assets market share, detailed preclinical assets market segments, market trends and opportunities, and any further data you may need to thrive in the preclinical assets industry. This preclinical assets market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Preclinical Assets Market Report Scope
Report AttributeDetails
Market Size Value In 2024 $5.83 billion
Revenue Forecast In 2033 $8.34 billion
Growth Rate CAGR of 9.3% from 2024 to 2033
Base Year For Estimation 2023
Actual Estimates/Historical Data 2018-2023
Forecast Period 2024 - 2028 - 2033
Market Representation Revenue in USD Billion and CAGR from 2024 to 2033
Segments Covered 1) By Service: Bioanalysis And DMPK (Drug Metabolism and Pharmacokinetic) studies, Toxicology Testing, Compound Management, Safety Pharmacology, Other Services
2) By Model Type: Patient Derived Organoid (PDO) Model, Patient Derived Xenograft Model
3) By End User: Biopharmaceutical Companies, Government Institutes, Other End-Users
Regional Scope Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Country Scope Australia; China; India; Indonesia; Japan; South Korea; Bangladesh; Thailand; Vietnam; Malaysia; Singapore; Philippines; Hong Kong; New Zealand; USA; Canada; Mexico; Brazil; Chile; Argentina; Colombia; Peru; France; Germany; UK; Austria; Belgium; Denmark; Finland; Ireland; Italy; Netherlands; Norway; Portugal; Spain; Sweden; Switzerland; Russia; Czech Republic; Poland; Romania; Ukraine; Saudi Arabia; Israel; Iran; Turkey; UAE; Egypt; Nigeria; South Africa
Key Companies Profiled Laboratory Corporation of America; IQVIA Inc.; ICON PLC; Eurofins Scientific SE; PPD Inc.; SGS SA; WuXi AppTec Co. Ltd.; Intertrek Group PLC; Charles River Laboratories International Inc.; Medpace Inc.; Pharmaron Beijing Co. Ltd.; Evotec SE; GenScript Biotech Corporation; Inotiv Inc.; SRI International Inc.; Shanghai Medicilon Inc.; Biocytogen Pharmaceuticals Beijing Co. Ltd.; AmplifyBio LLC; BioReliance Corporation; Pharmalegacy Laboratories Co. Ltd.; Precigen Inc.; ReproCELL Incorporated; InSphero AG; Crown Bioscience Inc.; Comparative Biosciences Inc.; TCG Lifesciences Pvt. Ltd.; InVivo Biosystems; Pharmatest Services Ltd; Domainex Limited; Viroclinics Xplore
Customization ScopeRequest for Sample
Pricing And Purchase OptionsExplore Purchase Options

    Table Of Contents

    1. Executive Summary

    2. Preclinical Assets Market Characteristics

    3. Preclinical Assets Market Trends And Strategies

    4. Preclinical Assets Market - Macro Economic Scenario

    4.1. Impact Of High Inflation On The Market

    4.2. Ukraine-Russia War Impact On The Market

    4.3. COVID-19 Impact On The Market

    5. Global Preclinical Assets Market Size and Growth

    5.1. Global Preclinical Assets Market Drivers and Restraints

    5.1.1. Drivers Of The Market

    5.1.2. Restraints Of The Market

    5.2. Global Preclinical Assets Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)

    5.3. Global Preclinical Assets Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

    6. Preclinical Assets Market Segmentation

    6.1. Global Preclinical Assets Market, Segmentation By Service, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    Bioanalysis And DMPK (Drug Metabolism And Pharmacokinetic) Studies

    Toxicology Testing

    Compound Management

    Safety Pharmacology

    Other Services

    6.2. Global Preclinical Assets Market, Segmentation By Model Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    Patient Derived Organoid (PDO) Model

    Patient Derived Xenograft Model

    6.3. Global Preclinical Assets Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    Biopharmaceutical Companies

    Government Institutes

    Other End-Users

    7. Preclinical Assets Market Regional And Country Analysis

    7.1. Global Preclinical Assets Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    7.2. Global Preclinical Assets Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    8. Asia-Pacific Preclinical Assets Market

    8.1. Asia-Pacific Preclinical Assets Market Overview

    Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

    8.2. Asia-Pacific Preclinical Assets Market, Segmentation By Service, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    8.3. Asia-Pacific Preclinical Assets Market, Segmentation By Model Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    8.4. Asia-Pacific Preclinical Assets Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    9. China Preclinical Assets Market

    9.1. China Preclinical Assets Market Overview

    9.2. China Preclinical Assets Market, Segmentation By Service, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

    9.3. China Preclinical Assets Market, Segmentation By Model Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

    9.4. China Preclinical Assets Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

    10. India Preclinical Assets Market

    10.1. India Preclinical Assets Market, Segmentation By Service, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    10.2. India Preclinical Assets Market, Segmentation By Model Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    10.3. India Preclinical Assets Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    11. Japan Preclinical Assets Market

    11.1. Japan Preclinical Assets Market Overview

    11.2. Japan Preclinical Assets Market, Segmentation By Service, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    11.3. Japan Preclinical Assets Market, Segmentation By Model Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    11.4. Japan Preclinical Assets Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    12. Australia Preclinical Assets Market

    12.1. Australia Preclinical Assets Market, Segmentation By Service, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    12.2. Australia Preclinical Assets Market, Segmentation By Model Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    12.3. Australia Preclinical Assets Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    13. Indonesia Preclinical Assets Market

    13.1. Indonesia Preclinical Assets Market, Segmentation By Service, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    13.2. Indonesia Preclinical Assets Market, Segmentation By Model Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    13.3. Indonesia Preclinical Assets Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    14. South Korea Preclinical Assets Market

    14.1. South Korea Preclinical Assets Market Overview

    14.2. South Korea Preclinical Assets Market, Segmentation By Service, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    14.3. South Korea Preclinical Assets Market, Segmentation By Model Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    14.4. South Korea Preclinical Assets Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    15. Western Europe Preclinical Assets Market

    15.1. Western Europe Preclinical Assets Market Overview

    15.2. Western Europe Preclinical Assets Market, Segmentation By Service, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    15.3. Western Europe Preclinical Assets Market, Segmentation By Model Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    15.4. Western Europe Preclinical Assets Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    16. UK Preclinical Assets Market

    16.1. UK Preclinical Assets Market, Segmentation By Service, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    16.2. UK Preclinical Assets Market, Segmentation By Model Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    16.3. UK Preclinical Assets Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    17. Germany Preclinical Assets Market

    17.1. Germany Preclinical Assets Market, Segmentation By Service, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    17.2. Germany Preclinical Assets Market, Segmentation By Model Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    17.3. Germany Preclinical Assets Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    18. France Preclinical Assets Market

    18.5. France Preclinical Assets Market, Segmentation By Service, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    18.6. France Preclinical Assets Market, Segmentation By Model Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    18.7. France Preclinical Assets Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    19. Italy Preclinical Assets Market

    19.9. Italy Preclinical Assets Market, Segmentation By Service, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    19.10. Italy Preclinical Assets Market, Segmentation By Model Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    19.11. Italy Preclinical Assets Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    20. Spain Preclinical Assets Market

    20.13. Spain Preclinical Assets Market, Segmentation By Service, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    20.14. Spain Preclinical Assets Market, Segmentation By Model Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    20.15. Spain Preclinical Assets Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    21. Eastern Europe Preclinical Assets Market

    21.1. Eastern Europe Preclinical Assets Market Overview

    21.2. Eastern Europe Preclinical Assets Market, Segmentation By Service, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    21.3. Eastern Europe Preclinical Assets Market, Segmentation By Model Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    21.4. Eastern Europe Preclinical Assets Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    22. Russia Preclinical Assets Market

    22.1. Russia Preclinical Assets Market, Segmentation By Service, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    22.2. Russia Preclinical Assets Market, Segmentation By Model Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    22.3. Russia Preclinical Assets Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    23. North America Preclinical Assets Market

    23.1. North America Preclinical Assets Market Overview

    23.2. North America Preclinical Assets Market, Segmentation By Service, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    23.3. North America Preclinical Assets Market, Segmentation By Model Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    23.4. North America Preclinical Assets Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    24. USA Preclinical Assets Market

    24.1. USA Preclinical Assets Market Overview

    24.2. USA Preclinical Assets Market, Segmentation By Service, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    24.3. USA Preclinical Assets Market, Segmentation By Model Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    24.4. USA Preclinical Assets Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    25. Canada Preclinical Assets Market

    25.1. Canada Preclinical Assets Market Overview

    25.2. Canada Preclinical Assets Market, Segmentation By Service, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    25.3. Canada Preclinical Assets Market, Segmentation By Model Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    25.4. Canada Preclinical Assets Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    26. South America Preclinical Assets Market

    26.1. South America Preclinical Assets Market Overview

    26.2. South America Preclinical Assets Market, Segmentation By Service, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    26.3. South America Preclinical Assets Market, Segmentation By Model Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    26.4. South America Preclinical Assets Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    27. Brazil Preclinical Assets Market

    27.1. Brazil Preclinical Assets Market, Segmentation By Service, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    27.2. Brazil Preclinical Assets Market, Segmentation By Model Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    27.3. Brazil Preclinical Assets Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    28. Middle East Preclinical Assets Market

    28.1. Middle East Preclinical Assets Market Overview

    28.2. Middle East Preclinical Assets Market, Segmentation By Service, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    28.3. Middle East Preclinical Assets Market, Segmentation By Model Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    28.4. Middle East Preclinical Assets Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    29. Africa Preclinical Assets Market

    29.1. Africa Preclinical Assets Market Overview

    29.2. Africa Preclinical Assets Market, Segmentation By Service, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    29.3. Africa Preclinical Assets Market, Segmentation By Model Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    29.4. Africa Preclinical Assets Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    30. Preclinical Assets Market Competitive Landscape And Company Profiles

    30.1. Preclinical Assets Market Competitive Landscape

    30.2. Preclinical Assets Market Company Profiles

    30.2.1. Laboratory Corporation of America

    30.2.1.1. Overview

    30.2.1.2. Products and Services

    30.2.1.3. Strategy

    30.2.1.4. Financial Performance

    30.2.2. IQVIA Inc.

    30.2.2.1. Overview

    30.2.2.2. Products and Services

    30.2.2.3. Strategy

    30.2.2.4. Financial Performance

    30.2.3. ICON PLC

    30.2.3.1. Overview

    30.2.3.2. Products and Services

    30.2.3.3. Strategy

    30.2.3.4. Financial Performance

    30.2.4. Eurofins Scientific SE

    30.2.4.1. Overview

    30.2.4.2. Products and Services

    30.2.4.3. Strategy

    30.2.4.4. Financial Performance

    30.2.5. PPD Inc.

    30.2.5.1. Overview

    30.2.5.2. Products and Services

    30.2.5.3. Strategy

    30.2.5.4. Financial Performance

    31. Preclinical Assets Market Other Major And Innovative Companies

    31.1. SGS SA

    31.2. WuXi AppTec Co. Ltd.

    31.3. Intertrek Group PLC

    31.4. Charles River Laboratories International Inc.

    31.5. Medpace Inc.

    31.6. Pharmaron Beijing Co. Ltd.

    31.7. Evotec SE

    31.8. GenScript Biotech Corporation

    31.9. Inotiv Inc.

    31.10. SRI International Inc.

    31.11. Shanghai Medicilon Inc.

    31.12. Biocytogen Pharmaceuticals Beijing Co. Ltd.

    31.13. AmplifyBio LLC

    31.14. BioReliance Corporation

    31.15. Pharmalegacy Laboratories Co. Ltd.

    32. Global Preclinical Assets Market Competitive Benchmarking

    33. Global Preclinical Assets Market Competitive Dashboard

    34. Key Mergers And Acquisitions In The Preclinical Assets Market

    35. Preclinical Assets Market Future Outlook and Potential Analysis

    35.1 Preclinical Assets Market In 2028 - Countries Offering Most New Opportunities

    35.2 Preclinical Assets Market In 2028 - Segments Offering Most New Opportunities

    35.3 Preclinical Assets Market In 2028 - Growth Strategies

    35.3.1 Market Trend Based Strategies

    35.3.2 Competitor Strategies

    36. Appendix

    36.1. Abbreviations

    36.2. Currencies

    36.3. Historic And Forecast Inflation Rates

    36.4. Research Inquiries

    36.5. The Business Research Company

    36.6. Copyright And Disclaimer

List Of Tables

    Table 1: Global Historic Market Growth, 2018-2023, $ Billion
  • Table 2: Global Forecast Market Growth, 2023-2028F, 2033F, $ Billion
  • Table 3: Global Preclinical Assets Market, Segmentation By Service, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 4: Global Preclinical Assets Market, Segmentation By Model Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 5: Global Preclinical Assets Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 6: Global Preclinical Assets Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 7: Global Preclinical Assets Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 8: Asia-Pacific, Preclinical Assets Market, Segmentation By Service, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 9: Asia-Pacific, Preclinical Assets Market, Segmentation By Model Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 10: Asia-Pacific, Preclinical Assets Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 11: China, Preclinical Assets Market, Segmentation By Service, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 12: China, Preclinical Assets Market, Segmentation By Model Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 13: China, Preclinical Assets Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 14: India, Preclinical Assets Market, Segmentation By Service, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 15: India, Preclinical Assets Market, Segmentation By Model Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 16: India, Preclinical Assets Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 17: Japan, Preclinical Assets Market, Segmentation By Service, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 18: Japan, Preclinical Assets Market, Segmentation By Model Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 19: Japan, Preclinical Assets Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 20: Australia, Preclinical Assets Market, Segmentation By Service, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 21: Australia, Preclinical Assets Market, Segmentation By Model Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 22: Australia, Preclinical Assets Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 23: Indonesia, Preclinical Assets Market, Segmentation By Service, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 24: Indonesia, Preclinical Assets Market, Segmentation By Model Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 25: Indonesia, Preclinical Assets Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 26: South Korea, Preclinical Assets Market, Segmentation By Service, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 27: South Korea, Preclinical Assets Market, Segmentation By Model Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 28: South Korea, Preclinical Assets Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 29: Western Europe, Preclinical Assets Market, Segmentation By Service, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 30: Western Europe, Preclinical Assets Market, Segmentation By Model Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 31: Western Europe, Preclinical Assets Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 32: UK, Preclinical Assets Market, Segmentation By Service, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 33: UK, Preclinical Assets Market, Segmentation By Model Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 34: UK, Preclinical Assets Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 35: Germany, Preclinical Assets Market, Segmentation By Service, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 36: Germany, Preclinical Assets Market, Segmentation By Model Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 37: Germany, Preclinical Assets Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 38: France, Preclinical Assets Market, Segmentation By Service, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 39: France, Preclinical Assets Market, Segmentation By Model Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 40: France, Preclinical Assets Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 41: Italy, Preclinical Assets Market, Segmentation By Service, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 42: Italy, Preclinical Assets Market, Segmentation By Model Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 43: Italy, Preclinical Assets Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 44: Spain, Preclinical Assets Market, Segmentation By Service, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 45: Spain, Preclinical Assets Market, Segmentation By Model Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 46: Spain, Preclinical Assets Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 47: Eastern Europe, Preclinical Assets Market, Segmentation By Service, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 48: Eastern Europe, Preclinical Assets Market, Segmentation By Model Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 49: Eastern Europe, Preclinical Assets Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 50: Russia, Preclinical Assets Market, Segmentation By Service, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 51: Russia, Preclinical Assets Market, Segmentation By Model Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 52: Russia, Preclinical Assets Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 53: North America, Preclinical Assets Market, Segmentation By Service, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 54: North America, Preclinical Assets Market, Segmentation By Model Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 55: North America, Preclinical Assets Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 56: USA, Preclinical Assets Market, Segmentation By Service, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 57: USA, Preclinical Assets Market, Segmentation By Model Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 58: USA, Preclinical Assets Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 59: Canada, Preclinical Assets Market, Segmentation By Service, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 60: Canada, Preclinical Assets Market, Segmentation By Model Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 61: Canada, Preclinical Assets Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 62: South America, Preclinical Assets Market, Segmentation By Service, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 63: South America, Preclinical Assets Market, Segmentation By Model Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 64: South America, Preclinical Assets Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 65: Brazil, Preclinical Assets Market, Segmentation By Service, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 66: Brazil, Preclinical Assets Market, Segmentation By Model Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 67: Brazil, Preclinical Assets Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 68: Middle East, Preclinical Assets Market, Segmentation By Service, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 69: Middle East, Preclinical Assets Market, Segmentation By Model Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 70: Middle East, Preclinical Assets Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 71: Africa, Preclinical Assets Market, Segmentation By Service, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 72: Africa, Preclinical Assets Market, Segmentation By Model Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 73: Africa, Preclinical Assets Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 74: Laboratory Corporation of America Financial Performance
  • Table 75: IQVIA Inc. Financial Performance
  • Table 76: ICON PLC Financial Performance
  • Table 77: Eurofins Scientific SE Financial Performance
  • Table 78: PPD Inc. Financial Performance

List Of Figures

    Figure 1: Global Historic Market Growth, 2018-2023, $ Billion
  • Figure 2: Global Forecast Market Growth, 2023-2028F, 2033F, $ Billion
  • Figure 3: Global Preclinical Assets Market, Segmentation By Service, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 4: Global Preclinical Assets Market, Segmentation By Model Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 5: Global Preclinical Assets Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 6: Global Preclinical Assets Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 7: Global Preclinical Assets Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 8: Asia-Pacific, Preclinical Assets Market, Segmentation By Service, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 9: Asia-Pacific, Preclinical Assets Market, Segmentation By Model Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 10: Asia-Pacific, Preclinical Assets Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 11: China, Preclinical Assets Market, Segmentation By Service, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 12: China, Preclinical Assets Market, Segmentation By Model Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 13: China, Preclinical Assets Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 14: India, Preclinical Assets Market, Segmentation By Service, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 15: India, Preclinical Assets Market, Segmentation By Model Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 16: India, Preclinical Assets Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 17: Japan, Preclinical Assets Market, Segmentation By Service, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 18: Japan, Preclinical Assets Market, Segmentation By Model Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 19: Japan, Preclinical Assets Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 20: Australia, Preclinical Assets Market, Segmentation By Service, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 21: Australia, Preclinical Assets Market, Segmentation By Model Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 22: Australia, Preclinical Assets Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 23: Indonesia, Preclinical Assets Market, Segmentation By Service, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 24: Indonesia, Preclinical Assets Market, Segmentation By Model Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 25: Indonesia, Preclinical Assets Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 26: South Korea, Preclinical Assets Market, Segmentation By Service, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 27: South Korea, Preclinical Assets Market, Segmentation By Model Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 28: South Korea, Preclinical Assets Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 29: Western Europe, Preclinical Assets Market, Segmentation By Service, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 30: Western Europe, Preclinical Assets Market, Segmentation By Model Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 31: Western Europe, Preclinical Assets Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 32: UK, Preclinical Assets Market, Segmentation By Service, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 33: UK, Preclinical Assets Market, Segmentation By Model Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 34: UK, Preclinical Assets Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 35: Germany, Preclinical Assets Market, Segmentation By Service, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 36: Germany, Preclinical Assets Market, Segmentation By Model Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 37: Germany, Preclinical Assets Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 38: France, Preclinical Assets Market, Segmentation By Service, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 39: France, Preclinical Assets Market, Segmentation By Model Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 40: France, Preclinical Assets Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 41: Italy, Preclinical Assets Market, Segmentation By Service, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 42: Italy, Preclinical Assets Market, Segmentation By Model Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 43: Italy, Preclinical Assets Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 44: Spain, Preclinical Assets Market, Segmentation By Service, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 45: Spain, Preclinical Assets Market, Segmentation By Model Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 46: Spain, Preclinical Assets Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 47: Eastern Europe, Preclinical Assets Market, Segmentation By Service, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 48: Eastern Europe, Preclinical Assets Market, Segmentation By Model Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 49: Eastern Europe, Preclinical Assets Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 50: Russia, Preclinical Assets Market, Segmentation By Service, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 51: Russia, Preclinical Assets Market, Segmentation By Model Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 52: Russia, Preclinical Assets Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 53: North America, Preclinical Assets Market, Segmentation By Service, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 54: North America, Preclinical Assets Market, Segmentation By Model Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 55: North America, Preclinical Assets Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 56: USA, Preclinical Assets Market, Segmentation By Service, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 57: USA, Preclinical Assets Market, Segmentation By Model Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 58: USA, Preclinical Assets Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 59: Canada, Preclinical Assets Market, Segmentation By Service, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 60: Canada, Preclinical Assets Market, Segmentation By Model Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 61: Canada, Preclinical Assets Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 62: South America, Preclinical Assets Market, Segmentation By Service, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 63: South America, Preclinical Assets Market, Segmentation By Model Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 64: South America, Preclinical Assets Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 65: Brazil, Preclinical Assets Market, Segmentation By Service, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 66: Brazil, Preclinical Assets Market, Segmentation By Model Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 67: Brazil, Preclinical Assets Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 68: Middle East, Preclinical Assets Market, Segmentation By Service, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 69: Middle East, Preclinical Assets Market, Segmentation By Model Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 70: Middle East, Preclinical Assets Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 71: Africa, Preclinical Assets Market, Segmentation By Service, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 72: Africa, Preclinical Assets Market, Segmentation By Model Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 73: Africa, Preclinical Assets Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 74: Laboratory Corporation of America Financial Performance
  • Figure 75: IQVIA Inc. Financial Performance
  • Figure 76: ICON PLC Financial Performance
  • Figure 77: Eurofins Scientific SE Financial Performance
  • Figure 78: PPD Inc. Financial Performance
Forecasting Till 2030: Opportunities And Strategies In The Global Value Based Care Payment Market – Includes Value Based Care Payment Market Analysis
Read More
How Will The Nuclear Medicine Market Grow In 2022?
Read More
What Is The Pediatric Imaging Market Overview In 2022?
Read More
Latest Healthcare Technology Management Market Growth Study 2022-2026 By The Business Research Company
Read More
The Business Research Company offers the hospital acquired infection control market research report 2022 with industry size, share, segments and market growth
Read More
The Business Research Company offers the multiplex assays market research report 2022 with industry size, share, segments and market growth
Read More
The Business Research Company offers the healthcare it consulting market research report 2022 with industry size, share, segments and market growth
Read More
The Business Research Company offers the renal biomarkers market research report 2022 with industry size, share, segments and market growth
Read More
Preclinical Imaging Global Market Report 2024 – By Modality (Optical Imaging Systems, Preclinical Nuclear Imaging Systems, Micro-magnetic Resonance Imaging Systems, Micro-Ultrasound Systems, Micro-computed Tomography Systems, Preclinical Photoacoustic Imaging Systems, Preclinical Magnetic Particle Imaging (MPI) Systems), By Reagents (Preclinical Optical Imaging Reagents, Preclinical Nuclear Imaging Reagents, Preclinical MRI Contrast Agents, Preclinical Ultrasound Contrast Agents, Preclinical CT Contrast Agents ), By End User (Hospital, Diagnostics Center, Other End-User) – Market Size, Trends, And Global Forecast 2024-2033
View Report
Preclinical CRO Global Market Report 2024 – By Service (Bioanalysis And DMPK Studies, Toxicology Testing, Compound Management, Chemistry, Safety Pharmacology, Others Services), By Type (Patient Derived Organoid (PDO) Model, Patient Derived Xenograft Model), By Animal Model (Small Animal Model, Large Animal Model), By Model System (In Vivo, In Vitro), By End User (Biopharmaceutical Companies, Government And Academic Institutes, Medical Device Companies, Other End-users) – Market Size, Trends, And Global Forecast 2024-2033
View Report
Lessors Of Nonfinancial Intangible Assets Global Market Report 2024 – By Type (Oil Royalty Companies, Patent Owners And Lessors), By Mode (Online, Offline) – Market Size, Trends, And Global Forecast 2024-2033
View Report
Defense IT Spending Global Market Report 2024 – By Type( Services, Hardware, Software ), By Force( Defense Forces, Civilian Forces ), By Application( IT Infrastructure, Cybersecurity, Defense Cloud Computing, Data Analytics, IT Application, Logistics and Assets Management, Other Applications ) – Market Size, Trends, And Global Forecast 2024-2033
View Report
Decentralized Finance Global Market Report 2024 – By Component (Blockchain Technology, Decentralized Applications (dApps), Smart Contracts), By Application (Assets Tokenization, Compliance And Identity, Marketplaces And Liquidity, Payments, Data And Analytics, Decentralized Exchanges, Prediction Industry, Stablecoins, Other Applications) – Market Size, Trends, And Global Forecast 2024-2033
View Report
Asset Finance Software Global Market Report 2024 – By Asset Type (Hard Assets, Soft Assets), By Deployment (Cloud, On-Premise), By Enterprise Type (Large Enterprises, Small And Medium Enterprises), By End-User (Transportation, Information Technology (IT) And Related Services, Construction, Agriculture, Medical Equipment, Banks, Industrial And Manufacturing Equipment, Other End Users) – Market Size, Trends, And Global Forecast 2024-2033
View Report
Asset-Backed Securities Global Market Report 2024 – By Type (Existing Assets, Future Cash Flow), By Application (Real Estate, Travel, Finance, Healthcare, Education), By Downstream Industry (Small And Medium Enterprises (SME), Large Enterprise) – Market Size, Trends, And Global Forecast 2024-2033
View Report
Lessors Of Nonfinancial Intangible Assets Global Market Report 2024 – By Type (Oil Royalty Companies, Patent Owners And Lessors), By Mode (Online, Offline) – Market Size, Trends, And Global Forecast 2024-2033
View Report

Frequently Asked Questions

What is the definition of the preclinical assets market?

A preclinical asset refers to all clinical trial supplies or equipment for preclinical development that encompasses the activities that link drug discovery in the laboratory to the initiation of human clinical trials. This phase precedes human clinical trials and entails essential feasibility assessments, iterative evaluations, and safety data gathering, typically performed on laboratory animals. For further insights on the preclinical assets market, request a sample here

How will the preclinical assets market drivers and restraints affect the preclinical assets market dynamics? What forces will shape the preclinical assets industry going forward?

The preclinical assets market major growth driver - Increasing Drug Discovery . For further insights on the preclinical assets market, request a sample here

What is the forecast market size or the forecast market value of the preclinical assets market?

The preclinical assetsmarket size has grown strongly in recent years. It will grow from $5.32 billion in 2023 to $5.83 billion in 2024 at a compound annual growth rate (CAGR) of 9.7%. The growth in the historic period can be attributed to drug development needs, advancements in biotechnology, regulatory requirements, research funding growth, collaborative research efforts. The preclinical assetsmarket size is expected to see strong growth in the next few years. It will grow to $8.34 billion in 2028 at a compound annual growth rate (CAGR) of 9.3%. The growth in the forecast period can be attributed to precision medicine and personalized therapies, ai and machine learning integration, biobanking expansion, focus on rare diseases, government initiatives and funding. Major trends in the forecast period include emergence of advanced imaging techniques, 3d organoid models, multi-omics integration, enhanced predictive models, automation and high throughput screening. For further insights on the preclinical assets market, request a sample here

How is the preclinical assets market segmented?

The preclinical assets market is segmented
1) By Service: Bioanalysis And DMPK (Drug Metabolism and Pharmacokinetic) studies, Toxicology Testing, Compound Management, Safety Pharmacology, Other Services
2) By Model Type: Patient Derived Organoid (PDO) Model, Patient Derived Xenograft Model
3) By End User: Biopharmaceutical Companies, Government Institutes, Other End-UsersFor further insights on the preclinical assets market, request a sample here

Which region has the largest share of the preclinical assets market? What are the other regions covered in the report?

North America was the largest region in the preclinical assetsmarket in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the preclinical assets market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa For further insights on the preclinical assets market, request a sample here.

Who are the major players in the preclinical assets market?

Major companies operating in the preclinical assets market report are Laboratory Corporation of America, IQVIA Inc., ICON PLC, Eurofins Scientific SE, PPD Inc., SGS SA, WuXi AppTec Co. Ltd., Intertrek Group PLC, Charles River Laboratories International Inc., Medpace Inc., Pharmaron Beijing Co. Ltd., Evotec SE, GenScript Biotech Corporation, Inotiv Inc., SRI International Inc., Shanghai Medicilon Inc., Biocytogen Pharmaceuticals Beijing Co. Ltd., AmplifyBio LLC, BioReliance Corporation, Pharmalegacy Laboratories Co. Ltd., Precigen Inc., ReproCELL Incorporated, InSphero AG, Crown Bioscience Inc., Comparative Biosciences Inc., TCG Lifesciences Pvt. Ltd., InVivo Biosystems, Pharmatest Services Ltd, Domainex Limited, Viroclinics Xplore For further insights on the preclinical assets market, request a sample here.

What are the key trends in the preclinical assets market?

Major trend in the preclinical assets market - Charles River Laboratories And Valo Health Introduce Logica, A Revolutionary Ai-Powered Solution For Optimized Preclinical Assets. For further insights on the preclinical assets market, request a sample here.

What are the major opportunities in the preclinical assets market? What are the strategies for the preclinical assets market?

For detailed insights on the major opportunities and strategies in the preclinical assets market, request a sample here.

How does the preclinical assets market relate to the overall economy and other similar markets?

For detailed insights on preclinical assets market's relation to the overall economy and other similar markets, request a sample here.

What are the latest mergers and acquisitions in the preclinical assets industry?

For detailed insights on the mergers and acquisitions in the preclinical assets industry, request a sample here.

What are the key dynamics influencing the preclinical assets market growth? SWOT analysis of the preclinical assets market.

For detailed insights on the key dynamics influencing the preclinical assets market growth and SWOT analysis of the preclinical assets industry, request a sample here.